公开(公告)号：US20220135668A1

公开(公告)日：2022-05-05

申请号：US17574980

申请日：2022-01-13

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24 ,  A61K39/00

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

公开(公告)号：US20200277368A1

公开(公告)日：2020-09-03

申请号：US16598714

申请日：2019-10-10

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

公开(公告)号：US20170218062A1

公开(公告)日：2017-08-03

申请号：US15487693

申请日：2017-04-14

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinctics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

公开(公告)号：US20160060337A1

公开(公告)日：2016-03-03

申请号：US14776222

申请日：2014-02-25

Applicant: AMGEN INC.

Inventor： John P. Gibbs ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/541 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

Abstract translation: 本发明涉及治疗牛皮癣的产品和方法。 该产品涉及抑制天然人IL-23同时保护IL-12的抗体。 一个例子描述了1期随机，双盲，安慰剂对照，上升单剂量研究，以评估健康受试者和中度受试者的抗IL-23抗体（AMG 139）的安全性，耐受性，药代动力学和药效学 到严重的牛皮癣。

公开(公告)号：US20160031983A1

公开(公告)日：2016-02-04

申请号：US14776281

申请日：2014-02-25

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

Abstract translation: 本发明涉及治疗克罗恩病的产品和方法。 该产品涉及抑制天然人IL-23同时保护IL-12的抗体。 一个例子描述了1期随机，双盲，安慰剂对照，上升多剂量研究，以评估健康受试者和轻度受试者中抗IL-23抗体（AMG 139）的安全性，耐受性，药代动力学和药效学 到严重的克罗恩病。